Sumit Majumder, MD
Infectious Disease · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 25
- 7 carriers
- Office
- 1
Offices
1 location
Hospitals listed: El Camino Health · Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
25 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Majumder’s office at (408) 374-5340 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
25 of 25 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A50797 · Current
Licensed to practise in California · since 1992 · expires 2027-12-31 · University of Calcutta Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$139,484
Medicare paid this office $139,484 for 327 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 234 | $62,688 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 295 | $48,246 | $144 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 115 | $24,258 | $98 |
| Return visit (30+ min) | 24 | $2,536 | $106 |
Who their Medicare patients are
327 Original Medicare patients in 2024. Average age 78 · Under 65 7% · 85 and older 29% · Women 47% · Also on Medicaid 30% · Health risk score 2.87. At or below the middle of the specialty; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 75% · Chronic kidney disease 52% · Diabetes 48% · Coronary heart disease 48% · Heart failure 43% · Atrial fibrillation 42% · Depression 39% · Dementia 35% · Cancer 25% · COPD 25% · Stroke 24%.
The office billed $260,002, Medicare allowed $178,115 and paid $139,484; for 1,578 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 327 | 1,578 | 78 | 2.87 | $260,002 | $139,484 |
| 2023 | 332 | 1,424 | 78 | 2.70 | $250,598 | $151,987 |
| 2022 | 403 | 1,725 | 77 | 2.58 | $286,631 | $174,486 |
| 2021 | 387 | 1,794 | 78 | 2.77 | $288,259 | $186,921 |
| 2020 | 371 | 1,717 | 77 | 2.34 | $256,778 | $179,619 |
| 2019 | 398 | 1,831 | 77 | 2.70 | $271,871 | $185,523 |
| 2018 | 391 | 1,723 | 77 | 2.43 | $253,119 | $165,716 |
| 2017 | 423 | 1,956 | 76 | 2.41 | $282,247 | $181,915 |
| 2016 | 391 | 2,205 | 76 | 2.79 | $306,473 | $210,189 |
| 2015 | 426 | 2,325 | 76 | 2.50 | $325,825 | $223,600 |
| 2014 | 372 | 2,195 | 75 | 2.41 | $306,918 | $212,968 |
| 2013 | 373 | 1,948 | 75 | 2.30 | $272,269 | $186,176 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 216 | $58,544 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 291 | $52,959 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 184 | $35,289 | $71 |
| Return visit (30+ min) | 19 | $3,058 | $118 |
| New patient visit (45+ min) | 11 | $1,731 | $157 |
2022: 5 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 338 | $67,324 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 229 | $59,273 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 228 | $42,438 | $64 |
| Return visit (30+ min) | 23 | $3,094 | $115 |
| New patient visit (45+ min) | 13 | $1,908 | $147 |
2021: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 246 | $68,861 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 317 | $66,580 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 218 | $43,298 | $67 |
| Return visit (30+ min) | 26 | $3,735 | $125 |
| New patient visit (45+ min) | 19 | $3,096 | $163 |
2020: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 240 | $72,357 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 281 | $60,176 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 199 | $36,342 | $67 |
| Return visit (30+ min) | 35 | $4,710 | $96 |
| New patient visit (45+ min) | 17 | $2,624 | $154 |
2019: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 307 | $66,999 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 256 | $63,736 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 221 | $44,820 | $65 |
| Return visit (30+ min) | 40 | $5,064 | $99 |
2018: 5 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 312 | $62,066 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 235 | $51,307 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 211 | $42,703 | $91 |
| Return visit (30+ min) | 35 | $4,530 | $92 |
| New patient visit (60+ min) | 11 | $2,043 | $186 |
2017: 6 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 330 | $64,849 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 269 | $59,970 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 184 | $41,483 | $90 |
| Return visit (30+ min) | 53 | $7,938 | $96 |
| New patient visit (45+ min) | 19 | $2,493 | $131 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 12 | $593 | $49 |
2016: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 227 | $77,035 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 283 | $59,536 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 240 | $53,948 | $64 |
| Return visit (30+ min) | 52 | $9,041 | $98 |
| New patient visit (45+ min) | 25 | $3,625 | $145 |
| Long return visit (40+ min) | 15 | $2,414 | $134 |
2015: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 244 | $78,843 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 302 | $68,291 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 255 | $58,351 | $64 |
| Return visit (30+ min) | 53 | $7,432 | $93 |
| New patient visit (45+ min) | 41 | $6,176 | $151 |
| Long return visit (40+ min) | 12 | $1,738 | $134 |
2014: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 239 | $87,946 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 288 | $61,578 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 221 | $47,461 | $64 |
| Return visit (30+ min) | 51 | $6,917 | $97 |
| New patient visit (45+ min) | 29 | $4,044 | $139 |
| Long return visit (40+ min) | 19 | $3,334 | $133 |
2013: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 235 | $79,643 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 259 | $51,646 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 194 | $36,107 | $62 |
| Return visit (30+ min) | 53 | $8,666 | $97 |
| New patient visit (45+ min) | 23 | $3,482 | $151 |
| Long return visit (40+ min) | 18 | $2,403 | $126 |
Medicaid work
$197 in 2023
Medicaid paid $197 for 12 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| 1ST HOSP IP/OBS HIGH 75 | 12 | $197 |
| 2023 | 12 | 1 | 12 | $197 |
| 2022 | 50 | 1 | 14 | $360 |
| 2020 | 21 | 1 | 14 | $110 |
See the largest Medicaid services in earlier years
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 50 | $360 |
2020
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 21 | $110 |
Drugs they prescribed that Part D paid
$174,349
Pharmacies billed $174,349 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 208) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
167 generic and 41 brand-name prescriptions · $174,349 in drug cost · 113 antibiotic prescriptions to 46 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Biktarvy | 19 | $77,843 | $4,097 |
| Tivicay | 13 | $29,934 | $2,303 |
| Ertapenem | 14 | $5,418 | $387 |
| Daptomycin | 11 | $2,890 | $263 |
| Ampicillin-Sulbactam | 14 | $649 | $46 |
See all 10 drugs
| Biktarvy | 19 | $77,843 | $4,097 |
| Tivicay | 13 | $29,934 | $2,303 |
| Ertapenem | 14 | $5,418 | $387 |
| Daptomycin | 11 | $2,890 | $263 |
| Ampicillin-Sulbactam | 14 | $649 | $46 |
| Cefazolin | 12 | $342 | $29 |
| Emtricitabine-Tenofovir Disop | 13 | $325 | $25 |
| Cephalexin | 12 | $210 | $17 |
| Amitriptyline | 12 | $144 | $12 |
| Azithromycin | 12 | $45 | $4 |
Year by year
| 2024 | 208 | 59 | 0% (0) | 20% | $174,349 |
| 2023 | 330 | 58 | 0% (0) | 16% | $240,326 |
| 2022 | 416 | 65 | 0% (0) | None | $243,505 |
| 2021 | 434 | 59 | 3% (14) | 15% | $236,638 |
| 2020 | 470 | 70 | None | 16% | $298,286 |
| 2019 | 514 | 84 | 2% (12) | 22% | $278,384 |
| 2018 | 539 | 91 | 2% (13) | 26% | $353,886 |
| 2017 | 731 | 124 | 2% (13) | 31% | $364,855 |
| 2016 | 687 | 134 | 2% (14) | 37% | $346,989 |
| 2015 | 652 | 133 | 3% (16) | 37% | $352,734 |
| 2014 | 505 | 118 | 4% (18) | 33% | $244,070 |
| 2013 | 477 | 114 | 5% (22) | 26% | $158,523 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Biktarvy | 14 | $56,817 | $4,058 |
| Tivicay | 17 | $37,802 | $2,224 |
| Efavirenz-Emtric-Tenofov Disop | 19 | $14,559 | $766 |
| Vancomycin | 24 | $7,124 | $297 |
| Efavirenz | 12 | $2,738 | $228 |
| Tenofovir Disoproxil | 13 | $2,454 | $189 |
| Ampicillin-Sulbactam | 14 | $2,448 | $175 |
| Lamivudine | 15 | $1,514 | $101 |
| Valacyclovir | 15 | $1,014 | $68 |
| Ceftriaxone | 18 | $674 | $37 |
| Zidovudine | 12 | $646 | $54 |
| Emtricitabine-Tenofovir Disop | 13 | $325 | $25 |
| Amitriptyline | 12 | $155 | $13 |
| Sulfamethoxazole-Trimethoprim | 19 | $53 | $3 |
2022: 17 drugs
| Tivicay | 26 | $53,795 | $2,069 |
| Genvoya | 12 | $46,193 | $3,849 |
| Biktarvy | 12 | $45,428 | $3,786 |
| Efavirenz-Emtric-Tenofov Disop | 12 | $14,362 | $1,197 |
| Atazanavir Sulfate | 13 | $7,043 | $542 |
| Ceftriaxone | 28 | $3,934 | $140 |
| Ampicillin-Sulbactam | 20 | $2,108 | $105 |
| Tenofovir Disoproxil | 13 | $1,847 | $142 |
| Lamivudine-Zidovudine | 13 | $1,829 | $141 |
| Lamivudine | 22 | $1,426 | $65 |
| Cephalexin | 12 | $787 | $66 |
| Sulfamethoxazole-Trimethoprim | 32 | $562 | $18 |
| Ciprofloxacin | 22 | $560 | $25 |
| Atorvastatin | 11 | $397 | $36 |
| Emtricitabine-Tenofovir Disop | 14 | $350 | $25 |
| Amitriptyline | 20 | $267 | $13 |
| Lisinopril | 13 | $25 | $2 |
2021: 21 drugs
| Tivicay | 25 | $48,714 | $1,949 |
| Atazanavir Sulfate | 14 | $10,727 | $766 |
| Emtricitabine-Tenofovir Disop | 16 | $10,492 | $656 |
| Ertapenem | 11 | $8,252 | $750 |
| Ceftriaxone | 19 | $2,610 | $137 |
| Tenofovir Disoproxil | 14 | $2,222 | $159 |
| Cefazolin | 18 | $1,877 | $104 |
| Lamivudine-Zidovudine | 13 | $1,634 | $126 |
| Lamivudine | 18 | $1,044 | $58 |
| Zidovudine | 13 | $792 | $61 |
| Amitriptyline | 26 | $406 | $16 |
| Ciprofloxacin | 18 | $387 | $22 |
| Sulfamethoxazole-Trimethoprim | 19 | $378 | $20 |
| Moxifloxacin | 17 | $360 | $21 |
| Atorvastatin | 17 | $213 | $13 |
| Acetaminophen-Codeine | 14 | $204 | $15 |
| Amoxicillin-Clavulanate Potass | 11 | $89 | $8 |
| Tamsulosin | 11 | $43 | $4 |
| Metoprolol | 13 | $21 | $2 |
| Lisinopril | 13 | $21 | $2 |
| Metformin | 12 | $19 | $2 |
2020: 19 drugs
| Truvada | 15 | $39,512 | $2,634 |
| Tivicay | 16 | $30,050 | $1,878 |
| Atazanavir Sulfate | 17 | $21,939 | $1,291 |
| Ertapenem | 11 | $10,943 | $995 |
| Ceftriaxone | 20 | $10,178 | $509 |
| Tenofovir Disoproxil | 15 | $2,797 | $186 |
| Ampicillin | 14 | $2,528 | $181 |
| Lamivudine-Zidovudine | 13 | $2,479 | $191 |
| Lamivudine | 20 | $1,497 | $75 |
| Zidovudine | 13 | $1,466 | $113 |
| Vancomycin | 15 | $1,445 | $96 |
| Rifampin | 16 | $674 | $42 |
| Clarithromycin | 15 | $481 | $32 |
| Amitriptyline | 26 | $412 | $16 |
| Sulfamethoxazole-Trimethoprim | 26 | $285 | $11 |
| Atorvastatin | 17 | $198 | $12 |
| Moxifloxacin | 12 | $172 | $14 |
| Ciprofloxacin | 18 | $171 | $9 |
| Lisinopril | 13 | $33 | $3 |
2019: 21 drugs
| Truvada | 19 | $44,507 | $2,342 |
| Tivicay | 13 | $23,758 | $1,828 |
| Atazanavir Sulfate | 19 | $14,161 | $745 |
| Efavirenz | 11 | $8,511 | $774 |
| Vancomycin | 28 | $4,786 | $171 |
| Tenofovir Disoproxil | 14 | $2,247 | $161 |
| Fluconazole | 14 | $1,919 | $137 |
| Lamivudine-Zidovudine | 12 | $1,647 | $137 |
| Ceftriaxone | 12 | $1,223 | $102 |
| Atovaquone-Proguanil | 14 | $939 | $67 |
| Moxifloxacin | 11 | $620 | $56 |
| Amitriptyline | 26 | $501 | $19 |
| Ciprofloxacin | 17 | $467 | $27 |
| Clarithromycin | 11 | $370 | $34 |
| Azithromycin | 26 | $255 | $10 |
| Acetaminophen-Codeine | 12 | $208 | $17 |
| Sulfamethoxazole-Trimethoprim | 16 | $129 | $8 |
| Gabapentin | 13 | $99 | $8 |
| Atorvastatin | 17 | $79 | $5 |
| Paroxetine | 12 | $39 | $3 |
| Metoprolol | 14 | $23 | $2 |
2018: 24 drugs
| Atripla | 18 | $70,292 | $3,905 |
| Truvada | 18 | $42,543 | $2,363 |
| Atazanavir Sulfate | 18 | $26,759 | $1,487 |
| Tivicay | 15 | $24,430 | $1,629 |
| Efavirenz | 11 | $9,020 | $820 |
| Fluconazole | 11 | $3,966 | $361 |
| Ceftriaxone | 13 | $3,674 | $283 |
| Atovaquone-Proguanil | 22 | $1,753 | $80 |
| Levofloxacin | 15 | $1,619 | $108 |
| Doxycycline Hyclate | 16 | $1,286 | $80 |
| Sodium Chloride | 20 | $1,211 | $61 |
| Lamivudine-Zidovudine | 12 | $1,174 | $98 |
| Cefazolin | 18 | $1,017 | $56 |
| Amoxicillin-Clavulanate Potass | 17 | $489 | $29 |
| Amitriptyline | 25 | $475 | $19 |
| Ciprofloxacin | 21 | $364 | $17 |
| Acetaminophen-Codeine | 13 | $223 | $17 |
| Gabapentin | 14 | $124 | $9 |
| Sulfamethoxazole-Trimethoprim | 16 | $111 | $7 |
| Azithromycin | 27 | $109 | $4 |
| Atorvastatin | 23 | $106 | $5 |
| Paroxetine | 14 | $70 | $5 |
| Metoprolol | 13 | $65 | $5 |
| Lisinopril | 11 | $26 | $2 |
2017: 27 drugs
| Atripla | 21 | $94,346 | $4,493 |
| Reyataz | 31 | $55,837 | $1,801 |
| Truvada | 19 | $42,057 | $2,214 |
| Triumeq | 12 | $30,069 | $2,506 |
| Tivicay | 13 | $19,989 | $1,538 |
| Vancomycin | 47 | $12,116 | $258 |
| Norvir | 17 | $6,527 | $384 |
| Viread | 13 | $3,614 | $278 |
| Imipenem-Cilastatin | 18 | $2,135 | $119 |
| Lamivudine-Zidovudine | 14 | $2,049 | $146 |
| Atovaquone-Proguanil | 23 | $1,552 | $67 |
| Levofloxacin | 12 | $1,188 | $99 |
| Sodium Chloride | 37 | $1,154 | $31 |
| Amoxicillin-Clavulanate Potass | 19 | $1,007 | $53 |
| Ceftriaxone | 13 | $959 | $74 |
| Epivir | 12 | $782 | $65 |
| Azithromycin | 25 | $660 | $26 |
| Ciprofloxacin | 67 | $569 | $8 |
| Amitriptyline | 25 | $444 | $18 |
| Valacyclovir | 12 | $420 | $35 |
| Sulfamethoxazole-Trimethoprim | 39 | $320 | $8 |
| Acetaminophen-Codeine | 12 | $213 | $18 |
| Gabapentin | 13 | $129 | $10 |
| Amoxicillin | 15 | $111 | $7 |
| Atorvastatin | 13 | $101 | $8 |
| Metoprolol | 13 | $65 | $5 |
| Paroxetine | 13 | $65 | $5 |
2016: 26 drugs
| Atripla | 26 | $79,820 | $3,070 |
| Reyataz | 48 | $66,884 | $1,393 |
| Truvada | 25 | $37,323 | $1,493 |
| Tivicay | 13 | $18,521 | $1,425 |
| Sustiva | 12 | $11,263 | $939 |
| Invanz | 13 | $9,258 | $712 |
| Norvir | 24 | $6,330 | $264 |
| Lamivudine-Zidovudine | 18 | $5,572 | $310 |
| Vancomycin | 12 | $3,772 | $314 |
| Ceftriaxone | 15 | $2,772 | $185 |
| Atovaquone-Proguanil | 35 | $2,553 | $73 |
| Sodium Chloride | 32 | $2,252 | $70 |
| Ampicillin-Sulbactam | 11 | $1,989 | $181 |
| Levofloxacin | 17 | $1,585 | $93 |
| Rifampin | 11 | $741 | $67 |
| Amoxicillin-Clavulanate Potass | 18 | $660 | $37 |
| Ciprofloxacin | 64 | $460 | $7 |
| Amitriptyline | 25 | $407 | $16 |
| Azithromycin | 16 | $367 | $23 |
| Sulfamethoxazole-Trimethoprim | 49 | $293 | $6 |
| Acetaminophen-Codeine | 14 | $250 | $18 |
| Atorvastatin | 23 | $195 | $8 |
| Gabapentin | 13 | $114 | $9 |
| Metoprolol | 13 | $65 | $5 |
| Paroxetine | 13 | $65 | $5 |
| Lisinopril | 12 | $26 | $2 |
2015: 25 drugs
| Atripla | 32 | $91,910 | $2,872 |
| Reyataz | 46 | $59,231 | $1,288 |
| Truvada | 29 | $39,301 | $1,355 |
| Combivir | 13 | $11,829 | $910 |
| Sustiva | 13 | $11,161 | $859 |
| Vancomycin | 20 | $9,716 | $486 |
| Edurant | 11 | $9,144 | $831 |
| Norvir | 23 | $6,022 | $262 |
| Ceftriaxone | 14 | $5,348 | $382 |
| Atovaquone-Proguanil | 32 | $3,071 | $96 |
| Sodium Chloride | 19 | $1,583 | $83 |
| Levofloxacin | 16 | $1,191 | $74 |
| Cefazolin | 12 | $890 | $74 |
| Epivir | 11 | $782 | $71 |
| Ciprofloxacin | 61 | $522 | $9 |
| Amitriptyline | 29 | $433 | $15 |
| Acetaminophen-Codeine | 16 | $318 | $20 |
| Amoxicillin-Clavulanate Potass | 11 | $285 | $26 |
| Sulfamethoxazole-Trimethoprim | 34 | $285 | $8 |
| Atorvastatin | 17 | $139 | $8 |
| Gabapentin | 14 | $137 | $10 |
| Simvastatin | 11 | $95 | $9 |
| Metoprolol | 14 | $70 | $5 |
| Paroxetine | 14 | $70 | $5 |
| Lisinopril | 13 | $28 | $2 |
2014: 17 drugs
| Atripla | 15 | $42,383 | $2,826 |
| Truvada | 29 | $37,712 | $1,300 |
| Reyataz | 18 | $21,742 | $1,208 |
| Kaletra | 13 | $10,783 | $829 |
| Edurant | 11 | $8,532 | $776 |
| Lamivudine Hbv | 12 | $4,309 | $359 |
| Ceftriaxone | 13 | $3,545 | $273 |
| Atovaquone-Proguanil | 20 | $1,644 | $82 |
| Ciprofloxacin | 74 | $782 | $11 |
| Sulfamethoxazole-Trimethoprim | 12 | $242 | $20 |
| Acetaminophen-Codeine | 16 | $238 | $15 |
| Amitriptyline | 26 | $234 | $9 |
| Gabapentin | 12 | $144 | $12 |
| Atorvastatin | 13 | $123 | $9 |
| Paroxetine | 12 | $68 | $6 |
| Lisinopril | 13 | $61 | $5 |
| Metoprolol | 12 | $60 | $5 |
2013: 21 drugs
| Truvada | 24 | $29,801 | $1,242 |
| Atripla | 11 | $21,124 | $1,920 |
| Reyataz | 12 | $13,429 | $1,119 |
| Vancomycin | 12 | $10,461 | $872 |
| Edurant | 13 | $9,325 | $717 |
| Kaletra | 11 | $8,647 | $786 |
| Lamivudine-Zidovudine | 12 | $8,443 | $704 |
| Epivir Hbv | 11 | $4,584 | $417 |
| Atovaquone-Proguanil | 17 | $1,624 | $96 |
| Amox Tr-Potassium Clavulanate | 20 | $1,347 | $67 |
| Lansoprazole | 13 | $537 | $41 |
| Ciprofloxacin | 51 | $507 | $10 |
| Azithromycin | 16 | $395 | $25 |
| Acetaminophen-Codeine | 19 | $304 | $16 |
| Gabapentin | 13 | $190 | $15 |
| Amitriptyline | 25 | $180 | $7 |
| Sulfamethoxazole-Trimethoprim | 14 | $179 | $13 |
| Atorvastatin | 12 | $162 | $13 |
| Paroxetine | 13 | $77 | $6 |
| Metoprolol | 13 | $65 | $5 |
| Lisinopril | 12 | $55 | $5 |
Money from drug and device companies
$125 in 2025
| 2025 | 1 | 1 | None | $125 |
| 2024 | 1 | 1 | None | $16 |
| 2019 | 1 | 1 | None | $13 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Melinta Therapeutics | Rezzayo | $125 | 1 payment
|
See the published payment
| Melinta Therapeutics | Meals · 2025-01-16 | Rezzayo | $125 |
See earlier years (2024, 2019)
2024: $16
| Gilead Sciences | None | $16 | 1 payment
|
2019: $13
| Merck Sharp & Dohme | Zerbaxa | $13 | 1 payment
|
Checkups this office reported
7 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 67.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Checked for fall riskOlder patients screened for fall risk | 89%That's most of the people this applied to. | 47 |
| Medications listed in the chartVisits where the current medication list was documented | 98%That's most of the people this applied to. | 120 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 0%That's few of the people this applied to. | 44 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 100%That's most of the people this applied to. | 43 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 4%That's few of the people this applied to. Better on this measure. | 50 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 81% | 116 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 92%That's most of the people this applied to. | 106 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- COVID-19 Vaccine Achievement for Practice Staff
- Did a security review of patient data
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- ONC-ACB Surveillance Attestation
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
- Records advance care plans
- Exempt from electronic case reporting
- Exempt from immunization registry reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
- Exempt from support electronic referral loops by receiving and reconciling health information
- Exempt from support electronic referral loops by sending health information
Professional record
- NPI
- 1245317692
- Licence
- CA A50797California A50797: Current · expires 2027-12-31
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 2076325
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X)
- Mailing address
- 14901 National Ave, Suite 202, Los Gatos, CA, 95032
- NPI first listed
- 2006-11-01
- NPI last updated
- 2013-11-14
This is when the NPI record was last certified, not a medical board exam.